High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

被引：0
|
作者：
Christopher Nyakutira
Daniel Röshammar
Emmanuel Chigutsa
Prosper Chonzi
Michael Ashton
Charles Nhachi
Collen Masimirembwa
机构：
[1] African Institute of Biomedical Science and Technology (AiBST),Department of DMPK & BAC
[2] University of Zimbabwe,Department of Clinical Pharmacology, School of Health Sciences
[3] Sahlgrenska Academy at Göteborg University,Department of Pharmacology
[4] University of Zimbabwe,School of Pharmacy
[5] Harare City Council Health Services,undefined
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Efavirenz; HIV/AIDS patients; CYP2B6 polymorphism; Pharmacokinetic modelling; NONMEM;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：357 / 365
页数：8
相关论文
共 50 条
  • [31] The clinical spectrum and G516T CYP2B6 single-nucleotide polymorphism in efavirenz drug-induced liver injury
    Sonderup, Mark
    Abdullah, Gadija
    Gogela, Neliswa
    Spearman, C. Wendy
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2018, 108 (08): : 692 - 692
  • [32] Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
    Meng, Xianmin
    Yin, Kang
    Wang, Jiangrong
    Dong, Ping
    Liu, Li
    Shen, Yinzhong
    Shen, Li
    Ma, Qing
    Lu, Hongzhou
    Cai, Weimin
    PLOS ONE, 2015, 10 (06):
  • [33] Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults
    Meng, Xian-min
    Li, Zi-ran
    Zheng, Xin-yin
    Liu, Yi-xi
    Niu, Wan-jie
    Qiu, Xiao-yan
    Lu, Hong-zhou
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 167
  • [34] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [35] Would a CYP2B6 test help HIV patients being treated with efavirenz?
    Sukasem, Chonlaphat
    Sungkanuparph, Somnuek
    PHARMACOGENOMICS, 2013, 14 (09) : 999 - 1001
  • [36] Pharmacogenetic screening: HLA-B*5701 vs. CYP2B6 G516T
    Lin, A. W. C.
    Yam, W-C
    Lam, H-Y
    To, S.
    Chan, D.
    Chan, K. C. W.
    Lee, S-S
    HIV MEDICINE, 2011, 12 (04) : 255 - 256
  • [37] Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G>T polymorphism
    Chantarangsu, Soranun
    Cressey, Tim
    Mahasirimongkol, Surakameth
    Tawon, Yardpiroon
    Ngo-Giang-Huong, Nicole
    Jourdain, Gonzague
    Lallemant, Marc
    Chantratita, Wasun
    MOLECULAR AND CELLULAR PROBES, 2007, 21 (5-6) : 408 - 411
  • [38] THE IMPACT OF CYP2B6 GENOTYPE ON EFAVIRENZ AUTO-INDUCTION: PHARMACOKINETICS MODEL AND SIMULATION
    Li, L.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S55 - S55
  • [39] CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India
    Ramachandran, Geetha
    Kumar, A. K. Hemanth
    Rajasekaran, Sikhamani
    Kumar, P.
    Ramesh, K.
    Anitha, S.
    Narendran, G.
    Menon, Pradeep
    Gomathi, C.
    Swaminathan, Soumya
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 863 - 868
  • [40] Cytochrome P4502B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda
    Penzak, S. R.
    Kabuye, G.
    Mugyenyi, P.
    Mbamanya, F.
    Natarajan, V.
    Alfaro, R. M.
    Kityo, C.
    Formentini, E.
    Masur, H.
    HIV MEDICINE, 2007, 8 (02) : 86 - 91
12345